我们的排名基于严谨的数据分析，而非观点。VerityRank使用专有综合评分（0-100）评估基因和细胞治疗公司，该评分基于四个权重相等的维度。
全球CGT收入（25%）：我们评估每家公司2025财年来自细胞治疗和基因治疗产品直销的收入，数据来源于经审计的财务报告和SEC文件。像吉利德/Kite（CGT销售额18亿美元）和传奇生物（CARVYKTI终端用户销售额19亿美元）这样的公司展示了我们所追踪的商业规模。
品牌影响力与临床采用（25%）：我们衡量全球治疗中心渗透率、医生偏好调查和患者倡导认可度。诺华作为首个获批CAR-T疗法（Kymriah）和重磅基因疗法Zolgensma的创造者，在品牌影响力指标上始终排名最高。
供应链与制造独立性（25%）：拥有并运营自有GMP认证制造设施的公司得分高于依赖外部CDMO的公司。Kite Pharma的四个设施内部网络体现了这一标准。
管线深度与创新（25%）：我们评估临床阶段项目、平台技术多样性以及下一代方法，包括异体细胞疗法、体内基因编辑和非病毒递送系统。所有数据均与临床试验注册库（ClinicalTrials.gov）、FDA/EMA批准数据库以及包括《自然生物技术》和《新英格兰医学杂志》在内的同行评审出版物进行交叉核对。
Our rankings are built on rigorous data analysis, not opinions. VerityRank evaluates gene and cell therapy companies using a proprietary Composite Score (0-100) based on four equally weighted dimensions.
Global CGT Revenue (25%): We assess each company's direct revenue from cell therapy and gene therapy product sales during the 2025 fiscal year, sourced from audited financial reports and SEC filings. Companies like Gilead/Kite ($1.8 billion in CGT sales) and Legend Biotech ($1.9 billion CARVYKTI end-user sales) demonstrate the commercial scale we track.
Brand Influence & Clinical Adoption (25%): We measure global treatment center penetration, physician preference surveys, and patient advocacy recognition. Novartis, as the creator of the first approved CAR-T therapy (Kymriah) and the blockbuster gene therapy Zolgensma, consistently ranks highest in brand influence metrics.
Supply Chain & Manufacturing Independence (25%): Companies that own and operate their GMP-certified manufacturing facilities receive higher scores than those relying on external CDMOs. Kite Pharma's four-facility internal network exemplifies this criterion.
Pipeline Depth & Innovation (25%): We evaluate clinical-stage programs, platform technology diversity, and next-generation approaches including allogeneic cell therapies, in vivo gene editing, and non-viral delivery systems. All data is cross-referenced against clinical trial registries (ClinicalTrials.gov), FDA/EMA approval databases, and peer-reviewed publications in journals including Nature Biotechnology and The New England Journal of Medicine.
领先的基因和细胞治疗公司展现出五项定义性能力，使其与竞争对手区分开来。
制造独立性：顶级CGT公司运营自己的GMP认证制造设施，而非外包给CDMO。凯特制药在美国和欧洲拥有四家全资细胞治疗工厂，实现了14天静脉到静脉的显著周转时间。百时美施贵宝在马萨诸塞州德文斯运营着一个244,000平方英尺的细胞治疗制造中心，并在荷兰莱顿设有新工厂。
临床数据卓越性：最成功的公司能产生改变实践的临床证据。传奇生物的CARVYKTI在重度预治疗的多发性骨髓瘤患者中显示出超过50%的持久完全缓解率，导致FDA标签包含了总生存期获益数据。福泰制药的CASGEVY通过令人信服的药物经济学数据实现了90%的美国保险覆盖。
全球商业基础设施：领导者已在20多个国家建立了治疗中心网络。诺华在三大洲的七个设施中运营CGT制造和分销，而传奇生物已将CARVYKTI扩展到18个市场和全球294个治疗中心。
监管导航专业知识：成功的CGT公司与FDA、EMA和PMDA监管机构保持紧密关系。凯特制药在2025年FDA撤销Yescarta和Tecartus的REMS要求，证明了长期安全验证来自持续的监管参与。
财务可持续性：重磅CGT产品产生的收入足以资助下一代研发。像Yescarta（15亿美元）、CARVYKTI（19亿美元）和Zolgensma（12.3亿美元）这样的产品为持续创新奠定了财务基础。缺乏这种商业规模的公司往往难以资助长期竞争力所需的资本密集型制造投资。
Leading gene and cell therapy companies demonstrate five defining capabilities that separate them from the competition.
Manufacturing Independence: Top-tier CGT companies operate their own GMP-certified manufacturing facilities rather than outsourcing to CDMOs. Kite Pharma maintains four wholly-owned cell therapy factories across the US and Europe, achieving a remarkable 14-day vein-to-vein turnaround time. Bristol Myers Squibb operates a 244,000-square-foot cell therapy manufacturing center in Devens, Massachusetts, and a new facility in Leiden, Netherlands.
Clinical Data Excellence: The most successful companies generate practice-changing clinical evidence. Legend Biotech's CARVYKTI demonstrated durable complete response rates exceeding 50% in heavily pretreated multiple myeloma patients, leading to FDA label inclusion of overall survival benefit data. Vertex Pharmaceuticals' CASGEVY achieved 90% US insurance coverage through convincing pharmacoeconomic data.
Global Commercial Infrastructure: Leaders have established treatment center networks spanning 20+ countries. Novartis operates CGT manufacturing and distribution across seven facilities on three continents, while Legend Biotech has expanded CARVYKTI to 18 markets and 294 treatment centers globally.
Regulatory Navigation Expertise: Successful CGT companies maintain strong relationships with FDA, EMA, and PMDA regulators. Kite Pharma's 2025 FDA REMS removal for Yescarta and Tecartus demonstrates the long-term safety validation that comes from sustained regulatory engagement.
Financial Sustainability: Blockbuster CGT products generate the revenue necessary to fund next-generation R&D. Products like Yescarta ($1.5 billion), CARVYKTI ($1.9 billion), and Zolgensma ($1.23 billion) create the financial foundation for continued innovation. Companies lacking this commercial scale often struggle to fund the capital-intensive manufacturing investments required for long-term competitiveness.
2025-2026年，全球基因和细胞治疗市场正经历四大变革趋势。
制造垂直整合：领先的CGT公司正在投入数十亿美元建设内部制造能力。Kite Pharma已扩展到四个专门的细胞治疗设施，而传奇生物在新泽西州拉里坦的工厂年产能达到10,000名患者。百时美施贵宝在荷兰莱顿增加了CAR-T生产中心，扩大了欧洲产能。这种从依赖CDMO转向自主制造的转变，代表了CGT价值链的根本性重组。
治疗线前移：CAR-T疗法正迅速从三线挽救治疗转向一线和二线治疗。CARVYKTI已获批用于更早期的多发性骨髓瘤治疗线，而Breyanzi（BMS）和Yescarta（Kite）正在争夺二线淋巴瘤适应症。每次治疗线前移，可治疗的患者群体将扩大3-5倍。
基因编辑商业化：首个CRISPR/Cas9疗法CASGEVY（Vertex/CRISPR Therapeutics）在2025年实现了90%的美国保险覆盖，并扩展到12个国家，证明了一次性治愈性基因编辑治疗的商业可行性。这一里程碑验证了基因编辑技术数十年的投资。
供应链地缘政治重组：《生物安全法案》和不断变化的贸易政策正在推动全球CGT供应链的根本性重组。Minaris Advanced Therapies的成立（源自药明康德ATU业务的剥离）体现了这一趋势。公司越来越多地投资于国内和盟国的制造能力，以减少地缘政治供应链风险，这在CGT制造领域创造了新的竞争格局。
The global gene and cell therapy market is experiencing four transformative trends in 2025-2026.
Manufacturing Vertical Integration: Leading CGT companies are investing billions of dollars in proprietary internal manufacturing capacity. Kite Pharma has expanded to four dedicated cell therapy facilities, while Legend Biotech's Raritan, New Jersey facility now has annual capacity for 10,000 patients. Bristol Myers Squibb added European capacity with its Leiden, Netherlands CAR-T production center. This shift from CDMO-dependency to self-manufacturing represents a fundamental restructuring of the CGT value chain.
Earlier Treatment Line Expansion: CAR-T therapies are rapidly moving from third-line salvage therapy to first-line and second-line treatment settings. CARVYKTI has been approved for earlier multiple myeloma treatment lines, while Breyanzi (BMS) and Yescarta (Kite) are competing for second-line lymphoma indications. Each line shift expands the addressable patient population by 3-5x.
Gene Editing Commercialization: The first CRISPR/Cas9 therapy, CASGEVY (Vertex/CRISPR Therapeutics), achieved 90% US insurance coverage in 2025 and expanded to 12 countries, demonstrating the commercial viability of one-time curative gene editing treatments. This milestone validates decades of investment in gene editing technology.
Supply Chain Geopolitical Restructuring: The BIOSECURE Act and evolving trade policies are driving a fundamental reconfiguration of global CGT supply chains. Minaris Advanced Therapies' formation from the WuXi ATU divestiture exemplifies this trend. Companies are increasingly investing in domestic and allied-nation manufacturing capacity to reduce geopolitical supply chain risk, creating a new competitive dynamic in the CGT manufacturing landscape.
CGT领域的采购和合作决策需要在五个关键维度上进行全面评估。
生产可靠性：评估每家公司按时、高质量交付产品的记录。Kite Pharma报告其行业领先的生产成功率超过95%，而依赖外部CDMO的公司则面临更大的变异性和日程冲突。评估警告信或与生产相关的FDA 483表格观察项的数量。
临床证据深度：除了主要终点，还要评估多年随访数据的应答持久性。传奇生物的CARVYKTI在重度预处理患者中显示出超过3年的持续完全缓解，而诺华的Kymriah自2017年获批以来已积累了近十年的真实世界证据。
全球可及性与支付方覆盖：一些创新疗法尽管临床成功，但在市场准入方面仍面临困难。Vertex Pharmaceuticals通过复杂的药品定价和基于结果的合同，为CASGEVY实现了90%的医疗补助和商业保险覆盖。Sarepta Therapeutics的ELEVIDYS通过与罗氏的合作，在美国、日本和部分欧洲市场获得了报销。
供应链韧性：评估生产地理位置和地缘政治风险敞口。拥有多大陆生产足迹的公司，如龙沙（全球30多个设施）和诺华（3大洲7个CGT站点），比单一区域生产商提供更大的供应连续性。
管线广度与下一代投资：考虑每家公司对下一代CGT技术的投入，包括通用型（现货型）细胞疗法、体内基因编辑和非病毒递送系统。百时美施贵宝收购Orbital Therapeutics表明其对RNA工程的承诺，而金斯瑞/ProBio的AI驱动“熄灯工厂”代表了未来的生产范式。
Procurement and partnership decisions in the CGT space require thorough evaluation across five critical dimensions.
Manufacturing Reliability: Assess each company's track record of on-time, high-quality product release. Kite Pharma reports industry-leading manufacturing success rates above 95%, while companies relying on external CDMOs face greater variability and scheduling conflicts. Evaluate the number of warning letters or manufacturing-related FDA Form 483 observations.
Clinical Evidence Depth: Beyond primary endpoints, evaluate durability of response with multi-year follow-up data. Legend Biotech's CARVYKTI shows sustained complete responses beyond 3 years in heavily pretreated patients, while Novartis' Kymriah has accumulated nearly a decade of real-world evidence since its 2017 approval.
Global Access & Payer Coverage: Some innovative therapies struggle with market access despite clinical success. Vertex Pharmaceuticals achieved 90% Medicaid and commercial insurance coverage for CASGEVY through sophisticated drug pricing and outcomes-based contracting. Sarepta Therapeutics' ELEVIDYS secures reimbursement in the US, Japan, and select European markets through its Roche partnership.
Supply Chain Resilience: Evaluate manufacturing geography and geopolitical risk exposure. Companies with multi-continent manufacturing footprints, like Lonza (30+ facilities globally) and Novartis (7 CGT sites across 3 continents), offer greater supply continuity than single-region producers.
Pipeline Breadth & Next-Generation Investment: Consider each company's commitment to next-generation CGT technologies including allogeneic (off-the-shelf) cell therapies, in vivo gene editing, and non-viral delivery systems. Bristol Myers Squibb's acquisition of Orbital Therapeutics signals commitment to RNA engineering, while GenScript/ProBio's AI-driven Lights-out factories represent the manufacturing paradigm of tomorrow.
多家公司正在开创下一代CGT技术，以解决当前在制造复杂性、成本和患者可及性方面的限制。
基因编辑领导者：Vertex Pharmaceuticals和CRISPR Therapeutics凭借CASGEVY在CRISPR基因编辑领域处于领先地位，并正在推进体内基因编辑方法，从而无需体外细胞处理。这些下一代疗法可能大幅降低治疗复杂性和成本。
RNA工程先驱：百时美施贵宝通过收购Orbital Therapeutics投资于RNA工程，目标是实现体内CAR-T生成，从而无需采集患者细胞。这种方法可能将CAR-T从个性化制造过程转变为现货型产品。
制造自动化：Lonza和Cytiva（Danaher）正在开发自动化、封闭系统的制造平台。Cytiva与Kite Pharma合作开发的Sefia系统，有望通过全自动化将CAR-T生产成本降低50%或更多。GenScript/ProBio正在实施熄灯式AI驱动工厂，用于全自动基因合成和质粒生产。
异体平台：多家公司正在推进异体（供体来源）细胞疗法，这些疗法可以大规模生产并用于多名患者。这些现货型产品可以消除自体疗法固有的制造瓶颈，可能将治疗成本从数十万美元降至数万美元。
今天投资于这些平台的公司，正在为2030年代的市场领导地位做准备，届时下一代CGT技术预计将使可治疗的患者群体从每年数万人扩大到数百万人。
Several companies are pioneering next-generation CGT technologies that address current limitations in manufacturing complexity, cost, and patient access.
Gene Editing Leaders: Vertex Pharmaceuticals and CRISPR Therapeutics lead in CRISPR-based gene editing with CASGEVY, and are advancing in vivo gene editing approaches that eliminate the need for ex vivo cell processing. These next-generation therapies could dramatically reduce treatment complexity and cost.
RNA Engineering Pioneers: Bristol Myers Squibb has invested in RNA engineering through its Orbital Therapeutics acquisition, targeting in vivo CAR-T generation that could eliminate the need for patient cell harvesting. This approach could transform CAR-T from a personalized manufacturing process to an off-the-shelf product.
Manufacturing Automation: Lonza and Cytiva (Danaher) are developing automated, closed-system manufacturing platforms. Cytiva's Sefia system, developed in partnership with Kite Pharma, promises to reduce CAR-T production costs by 50% or more through full automation. GenScript/ProBio is implementing Lights-out AI-driven factories for fully automated gene synthesis and plasmid production.
Allogeneic Platforms: Multiple companies are advancing allogeneic (donor-derived) cell therapies that can be manufactured at scale and used for multiple patients. These off-the-shelf products could eliminate the manufacturing bottleneck inherent in autologous therapies, potentially reducing costs from hundreds of thousands to tens of thousands of dollars per treatment.
Companies investing in these platforms today are positioning themselves for market leadership in the 2030s, when next-generation CGT technologies are expected to expand the addressable patient population from tens of thousands to millions annually.
